4DMT Q1 net loss $68.8M; cash $458M; 4D-150 Phase 3 enrollment complete

4D Molecular Therapeutics, Inc.

2026-Q1 EPS reported -$1.01 revenue$3,047,000

Cash $458M as of Mar 31, 2026, down from $514M; expected to fund ops into H2 2028.
Net loss $68.8M vs $48.0M YoY; R&D expenses rose to $65.0M on Phase 3 trial execution.
4D-150 wet AMD Phase 3 (4FRONT-1) randomization complete (N=523); topline data H1 2027.
PRISM Phase 2b 2-year data for wet AMD expected at a conference Q3 2026; SPECTRA DME 2-year data H2 2026.
4D-710 (CF) AEROW trial update expected H2 2026; 4D-175 (GA) evaluating strategic funding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

4D Molecular Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $3.0 million, net income Net loss was $68.8 million.

Period: the three months ended March 31, 2026
Revenue: $3.0 million
Net income: Net loss was $68.8 million
Result: reported results

Exact text from the filing

fund our operating expenses and capital expenditure requirements at least into the second half of 2028. Collaboration and License Revenue : Collaboration and license revenue was $3.0 million for the first quarter of 2026, as compared to an insignificant amount for the first quarter of 2025. The increase in revenue was primarily due to the clinical trial cost sharing

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.